Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 3/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.43 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.42 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11956986 | 0.88 | HTR1A (0.51) | IDO1TDO2SLC2A1STSKDM4E | |
| SCHEMBL11949130 | 0.87 | GPR119 (0.48) | IDO1TDO2STSKDM4EPKM | |
| SCHEMBL11949133 | 0.86 | IDO1 (0.47) | IDO1TDO2TGFBR1STSKDM4E | |
| SCHEMBL1346121 | 0.84 | MEN1 (0.47) | — | |
| SCHEMBL16825188 | 0.83 | TGFBR1 (0.56) | ALDH1A1TGFBR1SLC2A1STSKDM4E | |
| SCHEMBL27798463 | 0.83 | HTR1A (0.38) | — | |
| SCHEMBL28169019 | 0.82 | ALDH1A1 (0.62) | ALDH1A1TGFBR1STSBACE1KDM4E | |
| SCHEMBL16897956 | 0.82 | NR1H2 (0.46) | ALDH1A1STSKDM4EEPHX2HTT | |
| SCHEMBL1363304 | 0.81 | KDM4E (0.51) | TGFBR1STSKDM4EPKMGPR119 | |
| SCHEMBL2932442 | 0.81 | GPR183 (0.53) | ALDH1A1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303786-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO (JP) | 2013-11-14 | — | — | US | disclosed |
| US-20130303786-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8557998-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2013-10-15 | — | — | US | disclosed |
| US-8557998-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20120259122-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| US-20120259122-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8232405-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8232405-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8063223-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063223-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-20110118312-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118312-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20100113792-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113792-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303786-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | ALDH1A1 1260/4885IDO1 2499/4885TDO2 2139/4885 |
| US-20100113792-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | ALDH1A1 1260/4885IDO1 2499/4885TDO2 2139/4885 |
| US-20120259122-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | ALDH1A1 1260/4885IDO1 2499/4885TDO2 2139/4885 |
| US-20110118312-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | ALDH1A1 1260/4885IDO1 2499/4885TDO2 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.